| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Dual specificity protein kinase CLK2 |
|---|
| Ligand | BDBM293424 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_2290894 |
|---|
| IC50 | 3.6±n/a nM |
|---|
| Citation |  Lindberg, MF; Deau, E; Arfwedson, J; George, N; George, P; Alfonso, P; Corrionero, A; Meijer, L Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. J Med Chem66:4106-4130 (2023) [PubMed] |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Dual specificity protein kinase CLK2 |
|---|
| Name: | Dual specificity protein kinase CLK2 |
|---|
| Synonyms: | 2.7.12.1 | CDC-like kinase 2 | CDC-like kinase 2 (CLK2) | CDC2-like kinase 2 (CLK2) | CLK2 | CLK2_HUMAN |
|---|
| Type: | n/a |
|---|
| Mol. Mass.: | 60128.79 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P49760 |
|---|
| Residue: | 499 |
|---|
| Sequence: | MPHPRRYHSSERGSRGSYREHYRSRKHKRRRSRSWSSSSDRTRRRRREDSYHVRSRSSYD
DRSSDRRVYDRRYCGSYRRNDYSRDRGDAYYDTDYRHSYEYQRENSSYRSQRSSRRKHRR
RRRRSRTFSRSSSQHSSRRAKSVEDDAEGHLIYHVGDWLQERYEIVSTLGEGTFGRVVQC
VDHRRGGARVALKIIKNVEKYKEAARLEINVLEKINEKDPDNKNLCVQMFDWFDYHGHMC
ISFELLGLSTFDFLKDNNYLPYPIHQVRHMAFQLCQAVKFLHDNKLTHTDLKPENILFVN
SDYELTYNLEKKRDERSVKSTAVRVVDFGSATFDHEHHSTIVSTRHYRAPEVILELGWSQ
PCDVWSIGCIIFEYYVGFTLFQTHDNREHLAMMERILGPIPSRMIRKTRKQKYFYRGRLD
WDENTSAGRYVRENCKPLRRYLTSEAEEHHQLFDLIESMLEYEPAKRLTLGEALQHPFFA
RLRAEPPNKLWDSSRDISR
|
|
|
|---|
| BDBM293424 |
|---|
| n/a |
|---|
| Name | BDBM293424 |
|---|
| Synonyms: | US10106527, Compound 10 | US10106527, Compound 142 | US10106527, Compound 143 | US10106527, Compound 144 | US10106527, Compound 459 | US10544128, Compound 144 | US11548872, Compound 459 | US20230286945, Compound 459 | US9951048, Compound 459 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C24H25N7O |
|---|
| Mol. Mass. | 427.5016 |
|---|
| SMILES | CN1CCN(CC1)c1cc(ccn1)C(=O)Nc1cc2cc(ccc2cn1)-c1cnn(C)c1 |
|---|
| Structure | 
|
|---|
Search and Browse
